XBiotech (XBIT) Change in Accured Expenses (2014 - 2025)

XBiotech's Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $3.9 million for Q4 2025.

• In Q4 2025, Change in Accured Expenses rose 309.13% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $3.7 million (up 520.3% YoY), while the FY2025 annual figure was $3.7 million, up 520.3% from the prior year.
• Change in Accured Expenses for Q4 2025 stood at $3.9 million, up from $12000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.0 million in Q2 2022, with the low at -$3.6 million in Q3 2022.
• The 5-year median for Change in Accured Expenses is $103000.0 (2022), against an average of $247800.0.
• Peak annual rise in Change in Accured Expenses reached 2040.0% in 2022, while the deepest fall reached 9376.32% in 2022.
• XBiotech's Change in Accured Expenses stood at -$269000.0 in 2021, then tumbled by 43.12% to -$385000.0 in 2022, then surged by 56.36% to -$168000.0 in 2023, then plunged by 1008.93% to -$1.9 million in 2024, then jumped by 309.13% to $3.9 million in 2025.
• Business Quant data shows XBIT's Change in Accured Expenses at $3.9 million in Q4 2025, $12000.0 in Q3 2025, and -$1.9 million in Q2 2025.